BTS
PCRX icon

BB&T Securities’s Pacira BioSciences PCRX Stock Holding History

BB&T Securities’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,560
Closed -$205K – 955
2013
Q4 		$205K Buy
+3,560
New +$187K 0.01% 838

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

BB&T Securities's PCRX Position: Q1 2014 in Review

BB&T Securities sold out of Pacira BioSciences (PCRX) in Q1 2014, closing a stake of 3,560 shares — an estimated $205K sold.

BB&T Securities first reported a position in PCRX in Q4 2013 and held it in 1 quarter. The position peaked at $205K in Q4 2013. 160 funds tracked by Wall St. Rank hold PCRX as of Q1 2014.

  • BB&T Securities reported no remaining Pacira BioSciences position as of Q1 2014 after selling out during the quarter.
  • BB&T Securities sold 3,560 Pacira BioSciences shares in Q1 2014, an estimated $205K.
  • BB&T Securities first reported a position in Pacira BioSciences in Q4 2013 and held it in 1 quarter.
  • BB&T Securities's Pacira BioSciences position peaked at $205K in Q4 2013.
  • 160 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2014.

Based on BB&T Securities's 13F filing for Q1 2014, filed 15 Apr 2014.